No blend trials identified yet
No published clinical study of a premixed BPC-157 and TB-500 product was identified on PubMed. Evidence comes from each component separately. Reported in the cited paper.
SourceLoading…
Research Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →
The directory
83 listed
BioPeptide Technologies
LA Peptides
Main Peptides
Peak Lab Peptides
Royal Peptides
Ventra Sciences
ZC LabsNewsletter · Quarterly
Get notified about new lab results, price drops and supplier coupons before everyone else.
We respect your privacy. No spam.
Wolverine is a premixed research blend of BPC-157 and TB-500 supplied in a single vial. It targets tissue repair and recovery research, combining localised angiogenic action with systemic actin regulation without requiring two separate reconstitutions.
Vendor listings
Show prices as
47 listings · Wolverine
In stock10mgseen 4d ago
In stock10mgseen 3d ago
In stock20mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 4d ago
In stock20mgseen 3d ago
In stock10mgseen 5d ago
In stock10mgseen 5d ago
In stock10mgseen 3d ago
In stock10mgseen 4d ago
In stock10mgseen 5d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 5d ago
In stock20mgseen 6d ago
In stock20mgseen 3d ago
In stock10mgseen 3d ago
In stock20mgseen 4d ago
In stock10mgseen 3d ago
In stock20mgseen 3d ago
Overview
Wolverine is a premixed research blend of BPC-157 and TB-500 supplied in a single vial. It targets tissue repair and recovery research, combining localised angiogenic action with systemic actin regulation without requiring two separate reconstitutions.
What the research reports
Outcomes described across the published Wolverine literature and ongoing study. Read each as research context rather than a promised personal result.
Single vial blend convenience
Both peptides arrive premixed, removing the need to reconstitute, measure and track two separate vials across a protocol. Reported in research settings.
Combined repair mechanisms
Pairs localised angiogenic action with systemic actin regulation, the same rationale behind stacking the two peptides separately. Reported in research settings.
Consistent component ratio
A fixed ratio means each dose delivers the same proportion of both peptides, which makes a protocol easier to reproduce. Reported in research settings.
Recovery research application
Widely used in athletic recovery contexts for tendon, muscle and joint research, though the blend has no clinical trial. Reported in research settings.
Component level study support
Both peptides carry their own preclinical record, so the vial inherits the evidence of its parts rather than adding its own. Reported in research settings.
Dosage and protocol
Premixed vials vary by supplier, so the label ratio determines dosing. Component protocols use 250 to 500 mcg and 2 to 5 mg weekly. Figures describe study protocols, not a personal regimen.
Clinical evidence
The published Wolverine record, labeled by strength so you can see what is settled and what is still emerging.
No published clinical study of a premixed BPC-157 and TB-500 product was identified on PubMed. Evidence comes from each component separately. Reported in the cited paper.
SourceA 2021 case series reported significant improvement in 87.5 percent of 17 knee pain patients given intra-articular BPC 157 across one year of follow up. Reported in the cited paper.
SourceA 2016 review of thymosin beta-4 reported faster dermal repair in chronic wounds, the component evidence behind the TB-500 half of this vial. Reported in the cited paper.
SourceInteractions
Questions